Long-term results of sleeve lobectomy for lung cancer
Authors:
- Jocelyn GrégoireJGJocelyn Grégoire
- Jacques RouleauJRJacques Rouleau
- Jean DeslauriersJDJean Deslauriers
- 1 May 2000
- journal article
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 17 (5) , 550-556
Abstract
Sleeve lobectomy is a lung saving procedure indicated for central tumors for which the alternative is a pneumonectomy. Current controversies relate to the safety of the procedure and adequacy as a cancer operation. The aim of the study is to analyze long-term survival after sleeve lobectomy, particularly in relation with nodal status and histological type. The incidence and patterns of recurrences were reviewed. From 1972 to 1998, 184 patients (male 152, female 32) underwent sleeve resection for lung cancer. The mean age was 60+/-10 years (11-78 years), and the indications for operation were a central tumor (79%), peripheral tumor with nodal involvement (13%) and compromised pulmonary function (8%). The histological type was predominantly squamous (n=125, 68%), followed by non-squamous (n=50, 27%) and carcinoid tumors (n=9, 5%). Resection was complete in 161 patients (87%). The operative mortality was 1.6% (n=3). Follow-up was complete for the remaining 181 patients (mean, 5.7 years; range, 1 month-26 years). The survival at 5 and 10 years of all patients was 52 and 33%, respectively. Theses rates for patients with N0 status (n=97) were 63 and 48%, and 48 and 27% for those with N1 status (n=68; N0 vs. N1, P<0.05). An 8% survival rate was observed with N2 status (n=19) at 5 years, with no survivors after 7 years of follow-up. The 5 and 10 year survival was 56 and 34% for squamous carcinoma vs. 33 and 22% for non-squamous carcinoma (P<0.05). These rates were 58 and 38% for complete resection vs. 11 and 6% for incomplete resection at 5 and 10 years, respectively (P<0.05). Local recurrences occurred in 22% of cases, and the prevalence was statistically different between patients with N0 disease (14%) and N1 disease (23%; P=0.03), but not between N1 and N2 disease (42%; P=0.2). When local and distant recurrence were pooled together, the differences were highly significant between N0 (22%) and N1 (41%) disease (P=0.007), and between N0 and N2 (63%) disease (P=0.0002), but not between N1 and N2 disease (P=0.09). Sleeve lobectomy is a safe and effective therapy for patients with resectable lung cancer. The presence of N1 and N2 disease, or of non-squamous carcinoma significantly worsen the prognosis.Keywords
This publication has 20 references indexed in Scilit:
- Revisions in the International System for Staging Lung CancerChest, 1997
- Survival and function after sleeve lobectomy for lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 1996
- Long-term survival after bronchial sleeve resection: Univariate and multivariate analysesThe Annals of Thoracic Surgery, 1996
- Bronchoplastic and angioplastic techniques in the treatment of bronchogenic carcinomaThe Annals of Thoracic Surgery, 1993
- Current morbidity, mortality, and survival after bronchoplastic procedures for malignancyThe Annals of Thoracic Surgery, 1992
- Results in 104 patients undergoing bronchoplastic procedures for bronchial lesionsThe Annals of Thoracic Surgery, 1990
- Bronchoplastic and Bronchovascular Procedures of the Tracheobronchial Tree in the Management of Primary Lung CancerChest, 1989
- Results of Sleeve Lobectomy for Bronchogenic Carcinoma in 101 PatientsThe Annals of Thoracic Surgery, 1984
- Sleeve Lobectomy (Lobectomy and Bronchoplasty) for Bronchial CarcinomaThe Annals of Thoracic Surgery, 1983
- Multiple primary lung cancersThe Journal of Thoracic and Cardiovascular Surgery, 1975